AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36026477 — intervention group
Group type: COMPARATOR
Intervention: Reference meal (refined maize porridge with [58Fe]SO4)
Number of subjects: 20
Study 36026477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined maize porridge with crickets
Number of subjects: 20
Study 36026477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined maize porridge with [54Fe]SO4
Number of subjects: 20
Study 34551218 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP‐7000 90 mg
Number of subjects: 337
Study 34551218 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP‐7000 120 mg
Number of subjects: 337
Study 34551218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 35579143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dobutamine (infusion rates of 5, 10, 15, and 20 μg/kg/min)
Number of subjects: 186
Study 35579143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 186
Study 35914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution, 0.25%
Number of subjects: 54
Study 35914297 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 54
Study 33201041 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MOT training
Number of subjects: 62
Study 33201041 — intervention group
Group type: EXPERIMENTAL
Intervention: 2048 game
Number of subjects: 62
Study 33201041 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62
Study 33036661 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT (Instant MSC Product accompanying Autologous Chondron Transplantation)
Number of subjects: 60
Study 33036661 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 60
Study 33036661 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT
Number of subjects: 60
Study 35239009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 700
Study 34000494 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention administered at the time of the universal newborn hearing screen
Number of subjects: 112
Study 34000494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 32216109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg MTX administered subcutaneously once per week for 3 months
Number of subjects: 6
Study 32216109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg MTX administered subcutaneously
Number of subjects: 6
Study 32216109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg week−1 MTX (suggested dose)
Number of subjects: 6
Study 35917136 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote access control software (phase 3)
Number of subjects: 55
Study 35917136 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone assistance from investigators (phase 1)
Number of subjects: 55
Study 35917136 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Lions Club volunteers (phase 2)
Number of subjects: 55
Study 35917136 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation (phase 3)
Number of subjects: 55
Study 35917136 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (all phases)
Number of subjects: 55
Study 33766001 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package for healthcare professionals
Number of subjects: 35
Study 32348166 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs/ACEIs
Number of subjects: 126
Study 32348166 — intervention group
Group type: COMPARATOR
Intervention: non-ARBs/ACEIs
Number of subjects: 126
Study 35106719 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry Collaborative Care (TCC)
Number of subjects: 1004
Study 35106719 — intervention group
Group type: COMPARATOR
Intervention: Telepsychiatry/Telepsychology Enhanced Referral (TER)
Number of subjects: 1004
Study 34896445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocort 75 mg i.v. infusion plus i.m. saline injection
Number of subjects: 150
Study 34896445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocort 150 mg i.v. infusion plus i.m. saline injection
Number of subjects: 150
Study 34896445 — intervention group
Group type: COMPARATOR
Intervention: Depo‐Medrol® 120 mg i.m. injection plus i.v. saline infusion
Number of subjects: 150
Study 33358625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral calcification at 24 months
Number of subjects: 397
Study 33358625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic calcification at 24 months
Number of subjects: 397
Study 33358625 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular calcification prevalence
Number of subjects: 397
Study 33358625 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year progression of calcification
Number of subjects: 397
Study 32807165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified whey beverage (250 ml daily for 8 weeks)
Number of subjects: 46
Study 32807165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 36088785 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min per day, 2 mA, 2 weeks duration)
Number of subjects: 19
Study 36088785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified tDCS (2 × 20 min per day, 2 mA, 2 weeks duration)
Number of subjects: 19
Study 36088785 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned in the abstract)
Number of subjects: 19
Study 36293555 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN), 0.125 mg
Number of subjects: 9
Study 36293555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 36293555 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN)
Number of subjects: 9
Study 33113155 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2831781 (5 mg/kg)
Number of subjects: 27
Study 33113155 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2831781 (0.5, 1.5, and 5 mg/kg)
Number of subjects: 27
Study 33113155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 34727281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 187
Study 34727281 — intervention group
Group type: COMPARATOR
Intervention: Standard Nasal Cannula
Number of subjects: 187
Study 34259466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg orally, followed by a repeat dose after 90 minutes if contractions persisted, continued every 4 hours for 48 hours.
Number of subjects: 88
Study 34259466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 32770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Back in the Game smartphone application intervention (24-week Internet-delivered programme based on cognitive-behavioural therapy)
Number of subjects: 222
Study 32770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation care plus Back in the Game smartphone application
Number of subjects: 222
Study 32770983 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation care alone
Number of subjects: 222
Study 32770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Back in the Game smartphone application intervention
Number of subjects: 222
Study 35477496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of probiotic preparation for 4 weeks
Number of subjects: 43
Study 35477496 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of prebiotic (organic oat bran) supplementation for 4 weeks
Number of subjects: 43
Study 35477496 — intervention group
Group type: COMPARATOR
Intervention: 3 g of probiotic preparation or 5 g of prebiotic supplementation
Number of subjects: 43
Study 33203440 — intervention group
Group type: EXPERIMENTAL
Intervention: Online EMDR (R-TEP) intervention with a maximum of eight weekly sessions delivered by a trained psychological therapist.
Number of subjects: 26
Study 33203440 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus online EMDR (R-TEP) intervention.
Number of subjects: 26
Study 33203440 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control).
Number of subjects: 26
Study 33334933 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic biomarker panel (8 proteins)
Number of subjects: 157
Study 35237788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosurgical debridement
Number of subjects: 137
Study 35237788 — intervention group
Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 137
Study 32895647 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal-based oral rinse
Number of subjects: 48
Study 32895647 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine-based oral rinse
Number of subjects: 48
Study 32895647 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical mechanical debridement only
Number of subjects: 48
Study 36066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with SMART goals set by children over six months
Number of subjects: 0
Study 33631291 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE at 48 hours
Number of subjects: 79
Study 33631291 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100b and NSE biomarkers
Number of subjects: 79
Study 33631291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 79
Study 32393479 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthèse Diabète (experimental device)
Number of subjects: 112
Study 32393479 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable offloading devices (control group)
Number of subjects: 112
Study 34998371 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (3.2 μg/min)
Number of subjects: 100
Study 34998371 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (40 μg/min)
Number of subjects: 100
Study 34998371 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 100
Study 34998371 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 100
Study 34519194 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216
Study 34519194 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE with a behavioral approach (NSEB)
Number of subjects: 216
Study 34519194 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA)
Number of subjects: 216
Study 34519194 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE and NSEB
Number of subjects: 216
Study 32731978 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn sample 1
Number of subjects: 54
Study 32731978 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn sample 2
Number of subjects: 54
Study 35103603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial organized according to patient preferences (hybrid model with both on-site and remote visits)
Number of subjects: 628
Study 35103603 — intervention group
Group type: COMPARATOR
Intervention: Trial organized in a non-preferred model (not specified)
Number of subjects: 628
Study 32124409 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + BPT
Number of subjects: 182
Study 32124409 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 182
Study 35405661 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Support Intervention (CSI)
Number of subjects: 152
Study 35405661 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 152
Study 32476057 — intervention group
Group type: EXPERIMENTAL
Intervention: Current employment at baseline
Number of subjects: 0
Study 32476057 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted cumulative effect of employment over 8 follow-up visits
Number of subjects: 0
Study 33298663 — intervention group
Group type: EXPERIMENTAL
Intervention: J-DASH 1 diet 1×/day
Number of subjects: 40
Study 33298663 — intervention group
Group type: EXPERIMENTAL
Intervention: J-DASH 2 diet providing fish hamburger-patty 2×/day (5 days/week)
Number of subjects: 40
Study 33298663 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 40
Study 34686168 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless Steel (SS) ligatures
Number of subjects: 70
Study 34686168 — intervention group
Group type: COMPARATOR
Intervention: Elastomeric (EM) ligatures
Number of subjects: 70
Study 32900361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1-2 mg/kg)
Number of subjects: 120
Study 32900361 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg-i.v.)
Number of subjects: 120
Study 34133087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure plus sertraline (PE + SERT)
Number of subjects: 196
Study 34133087 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure plus placebo (PE + PLB)
Number of subjects: 196
Study 34133087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management (SERT + EMM)
Number of subjects: 196
Study 32006009 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans (Fe-Bean; 86.1 mg Fe/kg)
Number of subjects: 125
Study 32006009 — intervention group
Group type: COMPARATOR
Intervention: Conventional beans (control: 50.6 mg Fe/kg)
Number of subjects: 125
Study 35871951 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care (SOC) + Teduglutide (TED) for 2 months
Number of subjects: 6
Study 35871951 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 6
Study 35871951 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life survey
Number of subjects: 6
Study 33621970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Appraisals (CBM‐APP)
Number of subjects: 80
Study 33621970 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 80
Study 36150304 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy
Number of subjects: 8
Study 33545972 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide once daily (blinded) combined with glimepiride and metformin
Number of subjects: 0
Study 33545972 — intervention group
Group type: COMPARATOR
Intervention: liraglutide placebo once daily (blinded) combined with glimepiride and metformin
Number of subjects: 0
Study 32874044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon sutures
Number of subjects: 50
Study 32874044 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 50
Study 35882823 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose Bacillus coagulans TBC169
Number of subjects: 0
Study 35882823 — intervention group
Group type: COMPARATOR
Intervention: High-dose Bacillus coagulans TBC169
Number of subjects: 0
Study 35882823 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-control
Number of subjects: 0
Study 34571044 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine and tenofovir alafenamide
Number of subjects: 0
Study 34571044 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine and tenofovir disoproxil fumarate
Number of subjects: 0
Study 33730206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and neck-specific exercise (AE group)
Number of subjects: 139
Study 33730206 — intervention group
Group type: COMPARATOR
Intervention: Neck-specific exercise alone (control group)
Number of subjects: 139
Study 32949267 — intervention group
Group type: EXPERIMENTAL
Intervention: SB8 (bevacizumab biosimilar)
Number of subjects: 0
Study 32949267 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab‐EU
Number of subjects: 0
Study 32949267 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab‐US
Number of subjects: 0
Study 32949267 — intervention group
Group type: EXPERIMENTAL
Intervention: SB8
Number of subjects: 0
Study 32949267 — intervention group
Group type: EXPERIMENTAL
Intervention: SB8, bevacizumab‐EU, bevacizumab‐US
Number of subjects: 0
Study 35986664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 379
Study 35986664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 379
Study 35986664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 379
Study 35986664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 379
Study 35986664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 4 weeks (q4w)
Number of subjects: 379
Study 35986664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 34032604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at sites with the highest intubation rate
Number of subjects: 478
Study 34032604 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute neurologic recovery
Number of subjects: 478
Study 34032604 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute neurologic recovery
Number of subjects: 478
Study 34032604 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics including seizure precipitant, benzodiazepine dosing, and admission vital signs
Number of subjects: 478
Study 32279184 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted informed consent (additional informing video presentation)
Number of subjects: 74
Study 32279184 — intervention group
Group type: COMPARATOR
Intervention: Usual verbal-written informed consent
Number of subjects: 74
Study 32279184 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted informed consent
Number of subjects: 74
Study 35164796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 11617
Study 35164796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 11617
Study 34335455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory repetitive Transcranial Magnetic Stimulation (i-rTMS) followed by cognitive treatment for 15 days
Number of subjects: 0
Study 34335455 — intervention group
Group type: COMPARATOR
Intervention: SHAM control
Number of subjects: 0
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg inhaled
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 μg inhaled
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg twice daily (BID)
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 μg BID
Number of subjects: 85
Study 36243386 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 μg BID
Number of subjects: 85
Study 36243386 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 100, 200, 400 μg once daily (QD)
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg BID
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 μg BID
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 800 μg QD
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 644 μg/day
Number of subjects: 85
Study 32989770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn end-to-end anastomosis (ETE)
Number of subjects: 174
Study 32989770 — intervention group
Group type: COMPARATOR
Intervention: Semi-mechanical anastomosis (SMA)
Number of subjects: 174
Study 37073443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 36
Study 37073443 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 35073398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of six HLA-DRB1*0401-selective, β-cell peptides administered intradermally at doses of 10, 100, and 500 μg for 24 weeks.
Number of subjects: 0
Study 35073398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 35073398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of six HLA-DRB1*0401-selective, β-cell peptides
Number of subjects: 0
Study 34379856 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI‐F varnish
Number of subjects: 74
Study 34379856 — intervention group
Group type: COMPARATOR
Intervention: GI sealant (active control)
Number of subjects: 74
Study 33618181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (25 nM for 24 hours)
Number of subjects: 0
Study 33618181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (4% O2)
Number of subjects: 0
Study 33618181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS)
Number of subjects: 0
Study 33618181 — intervention group
Group type: COMPARATOR
Intervention: MNRR1 knockout cells
Number of subjects: 0
Study 32736583 — intervention group
Group type: EXPERIMENTAL
Intervention: eCREST (electronic Clinical Reasoning Educational Simulation Tool) - intervention group received three patient cases.
Number of subjects: 264
Study 32736583 — intervention group
Group type: COMPARATOR
Intervention: Teaching as usual - control group.
Number of subjects: 264
Study 33987556 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based contraceptive delivery (condoms, pills, injection, implant) during routine 40-day postpartum visit
Number of subjects: 208
Study 33987556 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone (comprehensive contraceptive counseling throughout antepartum care)
Number of subjects: 208
Study 32554690 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimpod® intervention
Number of subjects: 82
Study 32554690 — intervention group
Group type: COMPARATOR
Intervention: Audio relaxation (control)
Number of subjects: 82
Study 35945570 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp Messenger educational videos (twice a week) + conventional oral health education (single visit)
Number of subjects: 100
Study 35945570 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education (single visit)
Number of subjects: 100
Study 34455171 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip training
Number of subjects: 76
Study 34455171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76